Abstract:Infectious diseases are extremely important public health issues, where the design of effective, rapid, and convenient detection platforms is critical. In this study, we used conventional PCR coupled with SuCas12a2, a novel Cas12 family RNA-targeting nuclease, to develop a detection approach. SuCas12a2 possesses collateral cleavage activity and cuts the additional single-stranded RNA (ssRNA) added to the reaction system once the ternary complex RNA-SuCas12a2-CRISPR RNA (crRNA) is formed. SuCas12a2 is specifically activated, where the cleaved fluorescent-labeled probes release fluorescent signals, with the strength of the fluorescent signal being proportional to the concentration of nucleic acids specifically bound to crRNA. Simultaneous transcription and SuCas12a2 detection can be performed in a single tube by introducing the T7 promoter sequence into the forward primer. Entamoeba histolytica was used to evaluate the performance of the platform. PCR-SuCas12a2 has excellent capabilities, including high specificity with no cross-reactivity from other species and ultra-sensitivity that achieves a detection of one copy per reaction. There were five samples from amoebiasis patients confirmed by indirect immunofluorescence assay that were used as proof specimens, where the PCR-SuCas12a2 assay demonstrated 100% specificity. Furthermore, we replaced conventional PCR with recombinase polymerase amplification (RPA) to simplify the procedure for producing amplicons harboring the T7 promoter sequence. The sensitivity of the RPA-SuCas12a2 assay was 102 copies per reaction, which was inferior to PCR-SuCas12a2, and demonstrated 100% specificity. The technique shows robust performance and suggests great potential for point-of-care testing of other pathogens to facilitate effective management and control of the spread of diseases.

SATCAS: A CRISPR/Cas13a-based simultaneous amplification and testing platform for one-pot RNA detection and SNPs distinguish in clinical diagnosis

Development and application of sensitive, specific, and rapid CRISPR‐Cas13‐based diagnosis

Enhancement of trans-cleavage activity of Cas12a with engineered crRNA enables amplified nucleic acid detection

CRISPR-Cas12a2-based rapid and sensitive detection system for target nucleic acid

CESSAT: A chemical additive-enhanced single-step accurate CRISPR/Cas13 testing system for field-deployable ultrasensitive detection and genotyping of SARS-CoV-2 variants of concern

An Ultrasensitive, One-Pot RNA Detection Method Based on Rationally Engineered Cas9 Nickase-Assisted Isothermal Amplification Reaction.

Application of the amplification-free SERS-based CRISPR/Cas12a platform in the identification of SARS-CoV-2 from clinical samples

Preamplification-free ultra-fast and ultra-sensitive point-of-care testing via LwaCas13a

A Sensitive, Rapid, and Portable CasRx-based Diagnostic Assay for SARS-CoV-2.

Visual Detection of SARS-CoV-2 with a CRISPR/Cas12b-based Platform

Precise amplification-free detection of highly structured RNA with an enhanced SCas12a assay

CDetection.v2: One-pot assay for the detection of SARS-CoV-2

CRISPR-Cas14a with Competitive Isothermal Amplification for Rapid Visual Pathogen Diagnosis

Simple, sensitive, and visual detection of 12 respiratory pathogens with one‐pot‐RPA‐CRISPR/Cas12a assay

Rapid and accurate SERS assay of disease-related nucleic acids based on isothermal cascade signal amplifications of CRISPR/Cas13a system and catalytic hairpin assembly

Split crRNA with CRISPR-Cas12a enabling highly sensitive and multiplexed detection of RNA and DNA

Developing, characterizing and modeling CRISPR-based point-of-use pathogen diagnostics

Rapid detection of SARS-CoV-2 with CRISPR-Cas12a

Integrating PCR-free Amplification and Synergistic Sensing for Ultrasensitive and Rapid CRISPR/Cas12a-based SARS-CoV-2 Antigen Detection.

High-Throughput and Integrated CRISPR/Cas12a-Based Molecular Diagnosis Using a Deep Learning Enabled Microfluidic System

Development of a Rapid and Sensitive CasRx-Based Diagnostic Assay for SARS-CoV-2